Redhill Biopharma Partners with The Dot Corp and ixlayer for Enhanced Patient-Centric Solutions

Redhill Biopharma Leverages Strategic Collaboration to Enhance Patient-Centric Healthcare Solutions

Redhill Biopharma stands at the forefront of innovation in the biopharmaceutical industry, particularly with its focus on patient-centered care. A recent strategic collaboration between The Dot Corp and ixlayer highlights a significant movement towards enhancing direct-to-patient (DTP) healthcare solutions. This partnership, announced on December 5, 2025, aims to strengthen supply chain capabilities, which are critical for the successful deployment of at-home diagnostics and patient onboarding. By improving the processes of kitting, assembly, and fulfillment, ixlayer can better support pharmaceutical companies in delivering timely and effective healthcare solutions directly to patients.

The ixEngage platform, operated by ixlayer, integrates essential healthcare components, including labs, telehealth, and prescriptions. The platform is already making strides in the industry, having supported over 1,000 national programs and facilitated more than four million patient journeys. Such impressive statistics underscore the platform's robust compliance with regulatory standards, including CLIA certification for partner labs and adherence to HITRUST, SOC2, and HIPAA regulations. For Redhill Biopharma, aligning with partners like ixlayer not only enhances the operational efficiency of their programs but also reinforces their commitment to high-quality patient care and safety.

The Dot Corp’s involvement in this collaboration extends beyond logistics; it ensures quality control through rigorous checks and enables rapid deployment of new healthcare programs. By providing specialized kit design and fulfillment operations, The Dot Corp plays a vital role in scaling ixlayer's offerings, particularly in the realm of specialty diagnostics and high-volume patient populations. Jeff Shattuck, CEO of The Dot Corp, emphasizes a shared mission with ixlayer to reduce friction in biopharma programs reliant on timely testing and clear patient instructions. This partnership signifies a strategic advancement that promises to transform how biopharmaceutical companies deliver care, making it more efficient and accessible.

In addition to this collaboration, Redhill Biopharma continues to explore innovative healthcare solutions that enhance patient outcomes. The commitment to patient-centric care remains a cornerstone of the company's strategic direction as it navigates the complexities of the biopharmaceutical landscape. By fostering partnerships with organizations that prioritize quality and compliance, Redhill Biopharma aims to solidify its position as a leader in the industry.

Overall, the collaboration between The Dot Corp and ixlayer marks a pivotal development in the biopharma sector, paving the way for more efficient healthcare delivery systems that prioritize patient needs and streamline operational processes. Redhill Biopharma is well-positioned to leverage such advancements as it continues to focus on improving patient experiences and outcomes in a rapidly evolving healthcare environment.